197 related articles for article (PubMed ID: 37021793)
41. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
42. SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023.
Rahman ZA; Kebriaei P
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):779-785. PubMed ID: 37438208
[TBL] [Abstract][Full Text] [Related]
43. Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Aldoss I; Stiller T; Cao TM; Palmer JM; Thomas SH; Forman SJ; Pullarkat V
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1326-9. PubMed ID: 25842050
[TBL] [Abstract][Full Text] [Related]
44. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
45. [Current management of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Onizuka M
Rinsho Ketsueki; 2018; 59(10):2028-2035. PubMed ID: 30305505
[TBL] [Abstract][Full Text] [Related]
46. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R
Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250
[TBL] [Abstract][Full Text] [Related]
47. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
[TBL] [Abstract][Full Text] [Related]
48. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
[TBL] [Abstract][Full Text] [Related]
49. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
Wieduwilt MJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
[TBL] [Abstract][Full Text] [Related]
50. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.
Kebriaei P; Saliba R; Rondon G; Chiattone A; Luthra R; Anderlini P; Andersson B; Shpall E; Popat U; Jones R; Worth L; Ravandi F; Thomas D; O'Brien S; Kantarjian H; de Lima M; Giralt S; Champlin R
Biol Blood Marrow Transplant; 2012 Apr; 18(4):584-92. PubMed ID: 21867666
[TBL] [Abstract][Full Text] [Related]
51. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
Tharkar-Promod S; Johnson DP; Bennett SE; Dennis EM; Banowsky BG; Jones SS; Shearstone JR; Quayle SN; Min C; Jarpe M; Mosbruger T; Pomicter AD; Miles RR; Chen WY; Bhalla KN; Zweidler-McKay PA; Shrieve DC; Deininger MW; Chandrasekharan MB; Bhaskara S
Leukemia; 2018 Jan; 32(1):49-60. PubMed ID: 28579617
[TBL] [Abstract][Full Text] [Related]
52. Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.
El Fakih R; Jabbour E; Ravandi F; Hassanein M; Anjum F; Ahmed S; Kantarjian H
Am J Hematol; 2018 Feb; 93(2):286-295. PubMed ID: 28971501
[TBL] [Abstract][Full Text] [Related]
53. Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?
Haddad FG; Short NJ
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):213-217. PubMed ID: 36485089
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study.
Aubert L; Petit A; Bertrand Y; Ray-Lunven AF; Angoso M; Pluchart C; Millot F; Saultier P; Cheikh N; Pellier I; Plantaz D; Sirvent A; Thouvenin-Doublet S; Valduga J; Plat G; Rialland F; Henry C; Esvan M; Gandemer V
Pediatr Blood Cancer; 2022 Feb; 69(2):e29441. PubMed ID: 34854546
[TBL] [Abstract][Full Text] [Related]
55. Allogeneic Hematopoietic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Second Complete Remission.
Kaito S; Kurosawa S; Najima Y; Sakaida E; Shingai N; Fukuda T; Tachibana T; Uchida N; Ozawa Y; Sawa M; Nakazawa H; Ota S; Kato J; Nakamae H; Katayama Y; Eto T; Tanaka J; Kanda Y; Atsuta Y; Arai Y; Kako S;
Transplant Cell Ther; 2022 Jun; 28(6):326.e1-326.e10. PubMed ID: 35306218
[TBL] [Abstract][Full Text] [Related]
56. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
Yilmaz M; Kantarjian H; Ravandi-Kashani F; Short NJ; Jabbour E
Clin Adv Hematol Oncol; 2018 Mar; 16(3):216-223. PubMed ID: 29742077
[TBL] [Abstract][Full Text] [Related]
57. Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia.
Cho H; Kim Y; Yoon JH; Lee J; Lee GD; Son J; Han K; Lee S; Kim M
Bone Marrow Transplant; 2021 Aug; 56(8):1953-1963. PubMed ID: 33824439
[TBL] [Abstract][Full Text] [Related]
58. Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.
Kim K; Jabbour E; Short NJ; Kebriaei P; Kantarjian H; Ravandi F
Curr Oncol Rep; 2021 Jun; 23(8):95. PubMed ID: 34125415
[TBL] [Abstract][Full Text] [Related]
59. In the Era of BCR-ABL1 Inhibitors, Are We Closing the Survival Gap Between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in First Complete Remission?
Wieduwilt MJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):637-638. PubMed ID: 29474869
[No Abstract] [Full Text] [Related]
60. The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era - a surveillance, epidemiology, and end results database analysis.
Igwe IJ; Yang D; Merchant A; Merin N; Yaghmour G; Kelly K; Ramsingh G
Br J Haematol; 2017 Nov; 179(4):618-626. PubMed ID: 29047122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
